Abbott hopes to have first FDA-cleared NGAL test for kidney injury
This article was originally published in Clinica
Executive Summary
Abbott has filed a 510(k) application with the US FDA for a urine test to identify patients at risk of developing acute kidney injury (AKI). If approved, it will be the first diagnostic available in the US to measure the biomarker neutrophil gelatinase-associated lipocalin (NGAL), the company claims. The test is already CE marked for sale in Europe. Inverness Medical Innovations is also developing an NGAL test, which is available in Europe but not the US. Inverness' product analyses blood rather than urine, but both tests can diagnose AKI earlier in the disease process than the current gold standard, serum creatinine.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.